This week's Fierce Life Sciences is brought to you by Allucent.

Article: Harnessing Antibody-Drug Conjugates (ADCs) in Oncology: Pathways to Clinical Success

ADCs are reshaping cancer treatment. Once experimental, antibody-drug conjugates (ADCs) are now approved for breast, lung, and blood cancers. By combining targeted antibodies with potent payloads, ADCs offer a powerful, precise approach to therapy. Advances in linker and payload technology are boosting their efficacy and safety, paving the way for broader impact.